2026 Slated Board of Directors
The Society of Surgical Oncology (SSO) is pleased to announce the following new Officer and Board Members set to join the Board of Directors for the 2026-2029 term.
These individuals were nominated by SSO members and vetted by the Nominating Committee. Final selections were made by the Nominating Committee and current Board of Directors. They will replace those whose terms on the Board are ending, pending ratification of the slate at the 2026 SSO business meeting. Please click here to see the current leadership and those whose terms are ending.
Voting members will be asked to ratify the following new SSO Officer and Board of Directors Members prior to their installation at the Annual Business Meeting held during SSO 2026. Please look for more information on the Annual Business Meeting in early 2026.
Treasurer
Keith A. Delman, MD, FSSO, FACS
Dr. Delman is currently Professor of Surgery, Associate Chair of the Emory University Department of Surgery, and surgeon-in-chief for Emory at Grady Memorial Hospital. His practice focuses on complex cutaneous malignancies, and he has been a member of the Society of Surgical Oncology since 2004. As a member of the SSO he has served in several roles, including on the Training Committee, the Constitution and By-Laws Committee, the SCORE committee and the Board of Directors. He is currently the Chair of the Publications Committee and has also served in several roles on the editorial board of Annals of Surgical Oncology. In addition to his service to the SSO, Dr. Delman is a member of the American Surgical Association, Southern Surgical Association, American College of Surgeons, and is a consultant for the American Board of Surgery as a question writer for the CGSO examination and examiner for the certifying exam in Complex General Surgical Oncology.
After graduating from Cornell University with a bachelor’s degree in economics and completing his medical degree at SUNY Stony Brook, he went on to residency at Montefiore Medical Center-Albert Einstein College of Medicine. During residency, he completed a two-year research fellowship at Memorial Sloan-Kettering Cancer Center under the supervision of Dr. Yuman Fong. After residency, he completed his training with a clinical surgical oncology fellowship at the University of Texas-MD Anderson Cancer Center. In 2005, he began his faculty career at Emory University and has remained on staff since his initial appointment, providing care to patients with cutaneous malignancies and helping to lead the educational programs within the department, amongst other responsibilities.
He is married to a remarkable leader in obstetrics and gynecology, Dr. Dana Meaney-Delman, who is currently a professor at Emory and previously the center director for the National Center for Birth Defects and Developmental Disabilities at the Centers for Disease Control and Prevention. Together they have two daughters, Samantha, age 25 and Emma, age 22.
Board Member
Georgia M. Beasley, MD, MHSc
Dr. Beasley is an associate professor of surgery with tenure in the division of Surgical Oncology at Duke University with a secondary appointment as associate professor in the department of medicine. After playing 3 years in the women’s NBA, she began medical school. She obtained her MD (2008) and Masters of Health Science in clinical research (2010) from Duke University School of Medicine. She then completed general surgical residency at Duke University in 2015, followed by a fellowship in complex surgical oncology at the Ohio State University in 2017. She returned to Duke in 2017 as a faculty member. In 2019, she became co-director of the Duke Melanoma Program, and she serves as section chief of melanoma surgery. Dr. Beasley is a surgeon scientist with active involvement in clinical and translational research. She has mentored numerous students and residents in the laboratory. She is principal investigator of over 12 therapeutic clinical trials including novel intratumoral therapies. Her research focuses on the role of innate immunity in anti-tumor responses. She received the American Society for Clinical Investigation Young Physician-Scientist Award. In addition, she has authored over 120 publications centered on melanoma. She has received multiple internal and external funding including the Society of Surgical Oncology’s Young Investigator Award, NIH K08 mentored physician scientist award, Melanoma Research Alliance Grant, and is PI of a DOD team science award.
Board Member
Chandrajit P. Raut, MD, MSc, FACS, FSSO
Dr. Raut received his BA/BS from Stanford University, MSc from University of Oxford, and MD from Harvard Medical School. He completed his general surgery residency at Massachusetts General Hospital and surgical oncology fellowship at M.D. Anderson Cancer Center. He joined the Brigham faculty after completing his training. He was named Chief of the Brigham and Women’s Hospital Division of Surgical Oncology in 2019 and Chief of the integrated Mass General Brigham Division of Surgical Oncology in 2025.
Dr. Raut is an internationally renowned surgical oncologist who specializes in the multidisciplinary care of patients with soft tissue sarcoma. He is a prolific researcher and is currently funded on four NIH grants. He received two sequential NIH R01 grants to develop innovative chemotherapy-eluting films to reduce surgical bed sarcoma local recurrence rates. He is also PI of a new DOD/NIH Cancer Moonshot sarcoma proteogenomic study (“APOLLO 10”) leading a consortium of US institutions. Additionally, he has served as co-PI or institutional PI on several US and international phase 2 or phase 3 clinical trials evaluating neoadjuvant or adjuvant therapies in various sarcomas. In 2013, he co-founded the Transatlantic Australasian Retroperitoneal Sarcoma Working Group, an international multidisciplinary collaboration of over 200 centers across 5 continents advancing sarcoma care. He has authored over 300 papers and over 35 book chapters.
Dr. Raut is the former Program Director of the Mass General Brigham/Dana-Farber Complex General Surgical Oncology Fellowship Program at Harvard Medical School. He serves as Section Editor for sarcoma in the journals Cancer and Surgical Oncology Insights. He is one of two Chairs of the Surgery Committee in the cooperative group Alliance for Clinical Trials in Oncology. He is currently Chair of the Sarcoma Staging Panel for the forthcoming 9th edition of the AJCC Cancer Staging manual.
Online Election Results
The SSO is pleased to announce the results of the recent election that took place online from October 10 to October 24, 2025. These individuals were nominated by SSO members and vetted by the Nominating Committee. Final selections were made by the SSO voting members.
SSO Board of Directors,
Director-at-Large Three-Year Term (2026-2029)
Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
Dr. Fayanju is the Helen O. Dickens Presidential Professor in the Perelman School of Medicine at the University of Pennsylvania and Chief of the Division of Breast Surgery for Penn Medicine. An SSO member for more than a decade, she has served on the Research Committee (2021-2023), the Strategic Planning Task Force (2022-2023), the Breast Disease Site Working Group (2023-2025), the Value-based Health Care Task Force (2024-present), and the Annals of Surgical Oncology Editorial Board (2020-present). Her research and clinical practice are focused on elevating evidence-based, patient-centered care for individuals with malignant and benign breast disease.
Nominating Committee,
Three-Year Term (2026-2029)
Carlo M. Contreras, MD
Carlo M. Contreras, MD is an Associate Professor in the College of Medicine at the Ohio State University. He serves as an Associate Chief Medical Officer of the James Cancer Hospital and Medical Director of Ambulatory Services, and Associate Program Director for the OSU CGSO fellowship. Dr. Contreras specializes in skin and soft tissue cancers, including melanoma, Merkel cell carcinoma, squamous cell carcinoma and basal cell carcinoma.
Nominating Committee,
Two-Year Term (2026-2029)
Christina V. Angeles, MD, FSSO
Christina V. Angeles, MD, FSSO is an Associate Professor of Surgery and Dermatology and a faculty member of the Cancer Biology Graduate Program at the University of Michigan in the Division of Surgical Oncology. Her clinical practice encompasses caring for patients with soft tissue cancers including sarcoma, GIST, melanoma, and other cutaneous malignancies. As a surgeon-scientist, Dr. Angeles leads basic and translational research studying immune-mediated tumor protection to advance innovative therapies for melanoma and sarcoma.
Nominating Committee,
Community Practice Representative (2026-2029)
Camille Stewart, MD
Camille Stewart, MD, is dedicated to surgery and the multidisciplinary care of patients with cancer. Dr. Stewart specializes in diseases of the liver, gallbladder, pancreas, stomach, and small intestine, as well as melanoma and sarcoma.
Nominating Committee,
International Representative (2026-2029)
Ting-Chun (Tina) Kuo, MD, PhD, FACS, FSSO
Ting-Chun (Tina) Kuo, MD, PhD, FACS, is an Associate Professor of Surgery at National Taiwan University Hospital and a Visiting Scholar at UC San Diego. She specializes in endocrine and hepatopancreatobiliary surgery, with a focus on minimally invasive and imaging-guided approaches, XR-based surgical education, and international collaboration in surgical innovation.